From prevention to progression: can belzutifan-based strategies deliver across the RCC disease continuum?

HIF-2α signaling is a central driver of clear cell renal cell carcinoma biology. With regulatory approval of the HIF-2α inhibitor, belzutifan, in the third- and fourth-line refractory setting, therapeutic targeting of this pathway has entered clinical practice. At the 2026 ASCO GU Cancer Symposium, two randomized phase III trials evaluated earlier integration of belzutifan: LITESPARK-022 (belzutifan plus pembrolizumab vs pembrolizumab alone in the adjuvant setting) and LITESPARK-011 (belzutifan plus lenvatinib vs cabozantinib in the post-PD-(L)1 setting). LITESPARK-022 demonstrated a disease-free survival benefit (HR 0.72; 95% CI, 0.59-0.87; P = .0003), with early and sustained curve separation, though grade ≥3 adverse events doubled and overall survival data remain immature. LITESPARK-011 enrolled patients after progression on prior PD-(L)1 therapy in the metastatic setting. The combination improved median progression-free survival (PFS; 14.8 vs 10.7 months; HR 0.70), objective response rate (ORR; 52.6% vs 40%), and duration of response (23 vs 12 months), with a manageable toxicity profile. Together, these studies suggest that earlier targeting of HIF-2α biology may improve disease control and durability. However, patient selection, toxicity considerations, and the absence of mature OS data remain critical factors in determining the optimal role of belzutifan-based strategies across disease states.